Since both forms contain semaglutide and are FDA-approved for the same indication (chronic weight management), insurers apply the same PA criteria: BMI 30 or 27 with comorbidities, documented lifestyle modification, and potentially step therapy through cheaper medications
KIF5B-MET gene rearrangement with robust antitumor activity in response to crizotinib in lung adenocarcinoma
Pressure on a nerve may continue even when surrounding tissue irritation improves
Growth Opportunity Mapping across drug types (Semaglutide, Exenatide, Lixisenatide, Liraglutide, Dulaglutide, Others), routes of administration (Oral, Parenteral), indications (Diabetes, Obesity, Others), and regions
Exenatide injection
Am J Manag Care 28:S279S287 Hampl SE, Hassink SG, Skinner AC et al (2023) Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity